From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence in Rheumatoid Arthritis
Phase 4 evidence highlights the continued role of TNF inhibitors alongside newer biologic and targeted synthetic therapies in MTX-resistant RA. Trial heterogeneity reflects real world clinical complexity, underscoring the importance of treatment optimization, safety monitoring, and emerging precision strategies in contemporary RA management.
Authors
- Shaker Alsharif
Institutions
- Umm al-Qura University (SA)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2026-01-01
- DOI
- https://doi.org/10.2147/dddt.s581822
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00